Pharma Capital

PharmAust wins European patent for its cancer therapy drug

The company is now exploring commercial opportunities in major markets.
Euro symbol
PharmAust is developing cancer therapeutics for both humans and animals

PharmAust Limited (ASX:PAA) has received a patent in Europe for the use of its lead drug monepantel (MPL) as a cancer therapy with intellectual property (IP) protection until 2033.

The company is a clinical-stage company developing targeted cancer therapeutics for both humans and animals.

MPL is a drug approved by regulators for the treatment of veterinary parasitic infections.

The new patent relates to the use of aminoacetonitrile (an organic compound) derivatives for the treatment of intracellular pathway-related diseases.

Importantly, the new patent expands the range of therapeutic indications that can be targeted by PharmAust, enabling the company to explore new commercial opportunities in major markets.

The discovery by PharmAust that MPL has potent cancer suppressing activity has led to the company targeting MPL for the treatment of both veterinary and human cancers.

PharmAust had initiated trials at the University of Cambridge, Department of Veterinary Sciences in the UK last year.

The company’s subsidiary, Epichem, a contract synthetic drug manufacturer, is forecast to generate $3 million in revenues in 2017.



Register here to be notified of future PAA Company articles
View full PAA profile

PharmAust Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.